EU Regulators Recommend Oral Wegovy® for Weight Loss, Including Cardiovascular Benefits

summarizeSummary

European regulators have issued a positive opinion for Novo Nordisk's oral Wegovy® (semaglutide 25 mg) for weight management, including its cardiovascular benefits, paving the way for its launch in the EU.

check_boxKey Events

• CHMP Recommends Oral Wegovy® Approval

  The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for Wegovy® pill (oral semaglutide 25 mg) for weight management in the EU.

• Demonstrates Best-in-Class Efficacy

  The oral semaglutide 25 mg demonstrated a mean weight loss of 16.6% in the OASIS 4 trial, positioning it as a highly efficacious oral obesity treatment.

• Includes Cardiovascular Benefit Data

  The recommendation includes SELECT trial data in the label, showing that Wegovy® reduces the risk of major adverse cardiovascular events (MACE).

• Planned EU Launch in H2 2026

  Novo Nordisk plans to launch the Wegovy® pill in select markets outside the US in the second half of 2026, following strong demand observed in the US market.

auto_awesomeAnalysis

The positive opinion from the European Medicines Agency's CHMP for oral Wegovy® is a critical step towards expanding Novo Nordisk's blockbuster obesity treatment into the European market with a more convenient oral formulation. This development significantly broadens patient access and could drive substantial revenue growth, especially with the inclusion of data demonstrating a reduction in major adverse cardiovascular events (MACE) in the label. The company's plan to launch in H2 2026, following strong US demand, indicates high commercial potential.